RU2722449C2 - Полилигандные лекарственные конъюгаты и их применения - Google Patents

Полилигандные лекарственные конъюгаты и их применения Download PDF

Info

Publication number
RU2722449C2
RU2722449C2 RU2018104266A RU2018104266A RU2722449C2 RU 2722449 C2 RU2722449 C2 RU 2722449C2 RU 2018104266 A RU2018104266 A RU 2018104266A RU 2018104266 A RU2018104266 A RU 2018104266A RU 2722449 C2 RU2722449 C2 RU 2722449C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
cells
acceptable salt
cancer
receptor
Prior art date
Application number
RU2018104266A
Other languages
English (en)
Russian (ru)
Other versions
RU2018104266A3 (enExample
RU2018104266A (ru
Inventor
Баохуа Роберт ХУАН
Цзянь ДАЙ
Чжунбо ВАН
Сюэюань СЕ
Сяодун Лю
Синьли ХУ
Original Assignee
Кохерент Байофарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Application filed by Кохерент Байофарма filed Critical Кохерент Байофарма
Publication of RU2018104266A3 publication Critical patent/RU2018104266A3/ru
Publication of RU2018104266A publication Critical patent/RU2018104266A/ru
Application granted granted Critical
Publication of RU2722449C2 publication Critical patent/RU2722449C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018104266A 2015-08-11 2016-08-11 Полилигандные лекарственные конъюгаты и их применения RU2722449C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510489560.2 2015-08-11
CN201510489556.6 2015-08-11
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
RU2018104266A3 RU2018104266A3 (enExample) 2019-09-12
RU2018104266A RU2018104266A (ru) 2019-09-12
RU2722449C2 true RU2722449C2 (ru) 2020-06-01

Family

ID=57983917

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018104266A RU2722449C2 (ru) 2015-08-11 2016-08-11 Полилигандные лекарственные конъюгаты и их применения

Country Status (13)

Country Link
US (2) US11571480B2 (enExample)
EP (1) EP3334500B1 (enExample)
JP (3) JP6772199B2 (enExample)
KR (2) KR102301596B1 (enExample)
CN (3) CN108135881B (enExample)
AU (2) AU2016305703B2 (enExample)
CA (1) CA2987322C (enExample)
DK (1) DK3334500T3 (enExample)
ES (1) ES2877409T3 (enExample)
MX (1) MX381031B (enExample)
RU (1) RU2722449C2 (enExample)
WO (1) WO2017025057A1 (enExample)
ZA (1) ZA201707464B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148501A1 (en) 2009-06-26 2010-12-29 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CN108135881B (zh) * 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
US20200384069A1 (en) * 2017-12-01 2020-12-10 Soricimed Biopharma Inc. Trpv6 inhibitors and combination therapies for treating cancers
CA3084092A1 (en) * 2017-12-06 2019-06-13 Ontario Institute For Cancer Research (Oicr) Acyl hydrazone linkers, methods and uses thereof
EP3728273A4 (en) 2017-12-22 2021-12-29 Ontario Institute for Cancer Research (OICR) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
SG11202108182RA (en) * 2019-01-30 2021-08-30 Coherent Biopharma Suzhou Limited Bi-ligand drug conjugate and use thereof
EP4003321A4 (en) * 2019-07-22 2024-01-03 Purdue Research Foundation MULTIVALENT FIBROBLAST TARGETED AGENTS AND METHODS OF USE
US20230242979A1 (en) * 2019-08-20 2023-08-03 Egi Tech (Shen Zhen) Co., Limited Method for sequencing polynucleotides based on optical signal kinetics of luminescent labels and secondary luminescent signals
CA3170129A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
CN117337190A (zh) * 2021-01-07 2024-01-02 普渡研究基金会 叶酸受体靶向的缀合物、组合物和向中枢神经系统的递送
CA3224741A1 (en) * 2021-06-25 2022-12-29 Coherent Biopharma (Suzhou), Limited Ligand-drug conjugate and use thereof
CN116059392B (zh) * 2021-09-03 2025-02-28 同宜医药（苏州）有限公司 配体偶联物及其应用
CA3231134A1 (en) * 2021-09-08 2023-03-16 Coherent Biopharma (Suzhou) Limited Pharmaceutical preparation, preparation method therefor and use thereof
TW202327659A (zh) * 2021-10-19 2023-07-16 大陸商同宜醫藥（蘇州）有限公司 偶聯體藥物製劑及其製備方法和用途
CN116196408A (zh) * 2021-12-30 2023-06-02 思格(苏州)生物科技有限公司 一种新型免疫佐剂及其制备方法和应用
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
TW202421200A (zh) * 2022-11-09 2024-06-01 大陸商同宜醫藥（蘇州）有限公司 透過施用配體－藥物偶聯體治療癌症
CN120813385A (zh) * 2023-03-23 2025-10-17 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗卵巢癌
CN121001746A (zh) * 2023-04-26 2025-11-21 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US20080279868A1 (en) * 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
WO2014009774A1 (en) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
CN104667292A (zh) * 2015-02-02 2015-06-03 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
CN104784699A (zh) * 2014-01-20 2015-07-22 博瑞生物医药技术(苏州)有限公司 叶酸受体结合配体-药物偶联物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
EP1689443B1 (en) 2003-12-05 2019-03-13 Arrogene, Inc. Polymalic acid-based multifunctional drug delivery system
WO2006060664A2 (en) 2004-12-03 2006-06-08 The Uab Research Foundation Single-drug multi-ligand conjugates for targeted drug delivery
CN103893779A (zh) 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
WO2008034124A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
US20110230420A1 (en) 2008-11-17 2011-09-22 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
US8927694B2 (en) * 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2600900A4 (en) 2010-08-06 2014-11-19 Univ Illinois SUPRAMOLECULAR MULTIPLEX AGGREGATES FOR THE NONVIRAL OUTPUT OF GENETIC MATERIALS
ES2834992T3 (es) 2011-06-06 2021-06-21 Starpharma Pty Ltd Macromoléculas
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
US9545449B2 (en) * 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
KR20150030698A (ko) * 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
AU2013355324A1 (en) 2012-12-04 2015-05-21 Abbvie Inc. Blood-brain barrier (BBB) penetrating dual specific binding proteins
WO2014086835A1 (en) 2012-12-05 2014-06-12 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
CA2907181C (en) * 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3294810A4 (en) * 2015-05-12 2019-01-02 Blinkbio Inc. Silicon based drug conjugates and methods of using same
CN108135881B (zh) * 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
JP2020164335A (ja) * 2019-03-28 2020-10-08 イビデン株式会社 ハニカム構造体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US20080279868A1 (en) * 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
WO2014009774A1 (en) * 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
CN104784699A (zh) * 2014-01-20 2015-07-22 博瑞生物医药技术(苏州)有限公司 叶酸受体结合配体-药物偶联物
CN104667292A (zh) * 2015-02-02 2015-06-03 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
. BADR M. et al. Methotrexate-gelonin conjugate - an inhibitor of MCF-7 cells expressing the dihydrofolate receptor.Biol Chem. 2014 Dec;395(12):1461-6. doi: 10.1515/hsz-2013-0270. *
AHMAD A. et al. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited. *
AHMAD A. et al. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited. BADR M. et al. Methotrexate-gelonin conjugate - an inhibitor of MCF-7 cells expressing the dihydrofolate receptor.Biol Chem. 2014 Dec;395(12):1461-6. doi: 10.1515/hsz-2013-0270. *
DOSIO F. et al. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Toxins (Basel). 2011 Jul;3(7):848-83. doi: 10.3390/toxins3070848. Epub 2011 Jul 14. *

Also Published As

Publication number Publication date
AU2016305703B2 (en) 2019-07-25
JP6772199B2 (ja) 2020-10-21
CN111617250B (zh) 2022-07-01
KR20200071152A (ko) 2020-06-18
KR102301596B1 (ko) 2021-09-14
KR20180033513A (ko) 2018-04-03
MX381031B (es) 2025-03-12
JP2021006549A (ja) 2021-01-21
EP3334500A1 (en) 2018-06-20
HK1250634A1 (zh) 2019-01-11
CN108135881B (zh) 2020-11-13
RU2018104266A3 (enExample) 2019-09-12
AU2019240611B2 (en) 2021-09-09
KR102464778B1 (ko) 2022-11-07
RU2018104266A (ru) 2019-09-12
JP2018529632A (ja) 2018-10-11
CA2987322C (en) 2020-02-11
US20180200377A1 (en) 2018-07-19
JP2023025151A (ja) 2023-02-21
CN112263683A (zh) 2021-01-26
JP7573401B2 (ja) 2024-10-25
EP3334500A4 (en) 2019-04-03
DK3334500T3 (da) 2021-06-21
AU2019240611A1 (en) 2019-10-17
CN108135881A (zh) 2018-06-08
CN111617250A (zh) 2020-09-04
AU2016305703A1 (en) 2017-11-23
WO2017025057A1 (en) 2017-02-16
CA2987322A1 (en) 2017-02-16
US11571480B2 (en) 2023-02-07
ZA201707464B (en) 2021-05-26
ES2877409T3 (es) 2021-11-16
MX2018001723A (es) 2018-05-17
US20240100175A1 (en) 2024-03-28
EP3334500B1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
RU2722449C2 (ru) Полилигандные лекарственные конъюгаты и их применения
CN113453720B (zh) 双配体药物偶联体及其用途
CN109513010B (zh) 肿瘤细胞特异性响应的自组装药物纳米缀合物
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
CN106466485B (zh) 一种具有细胞内吞介导功能的靶向配体-药物偶联体
KR102831503B1 (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
HK40036786A (en) Multi-ligand drug conjugates and uses thereof
HK40036786B (zh) 多配体药物偶联体及其用途
HK1250634B (zh) 多配体药物偶联体及其用途
HK1253921B (en) Multi-ligand drug conjugates and uses thereof
RU2820346C2 (ru) Билигандный конъюгат лекарственного средства и его применение
HK40052006A (en) Bi-ligand drug conjugate and use thereof
HK40061762A (en) Bi-ligand drug conjugate and use thereof

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20210608